$126.3 Million In Total Gross Proceeds from Warrant Distribution. Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam. Over 735 Patients Have Completed a Phase 3 ...
Shares of biotech outfit Cassava Sciences Inc. fell after the publication Science reported Thursday that an investigation accused a neuroscientist who often collaborated with the company of ...
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease. Results corroborate prior research from other academic researchers. These data once ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City University of New York ...
A scientist who advises Cassava Sciences, a biotech under investigation by the Securities and Exchange Commission, engaged in “egregious misconduct” in his drug and other research, according to an ...
Good biotech companies develop and commercialize medicines that are safe and effective. Good medicines tend to be the result of good science. And while defining good science is beyond the scope of ...
The controversy about alleged data manipulation related to simufilam was stirred up again by a leaked report. Cassava's response noted that the report from CUNY didn't make any findings of data ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results